Showing 641 - 660 results of 101,016 for search '(( i ex decrease ) OR ( 5 ((((step decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.44s Refine Results
  1. 641
  2. 642
  3. 643
  4. 644
  5. 645

    Expansion of murine bone marrow cells <i>ex vivo</i> with Tat-MYC and Tat-Bcl-2. FACS analysis shows a continuous enrichment of the c-Kit<sup>+</sup>/Sca-1<sup>+</sup> population (lin<sup>−</sup>) whereas all other cell types decrease over a 25 day period. by Gregory A. Bird (623578)

    Published 2014
    “…<p>Expansion of murine bone marrow cells <i>ex vivo</i> with Tat-MYC and Tat-Bcl-2. FACS analysis shows a continuous enrichment of the c-Kit<sup>+</sup>/Sca-1<sup>+</sup> population (lin<sup>−</sup>) whereas all other cell types decrease over a 25 day period.…”
  6. 646
  7. 647
  8. 648
  9. 649
  10. 650
  11. 651
  12. 652
  13. 653
  14. 654
  15. 655
  16. 656
  17. 657
  18. 658

    Differential Inhibition of <i>Ex-Vivo</i> Tumor Kinase Activity by Vemurafenib in <i>BRAF</i>(V600E) and <i>BRAF</i> Wild-Type Metastatic Malignant Melanoma by Andliena Tahiri (452291)

    Published 2013
    “…While basal phosphorylation profiles were similar in <i>BRAF</i> wild-type and <i>BRAF</i>(V600E) tumors, analysis with <i>ex-vivo</i> vemurafenib treatment identified a subset of 40 kinase substrates showing stronger inhibition in <i>BRAF</i>(V600E) tumor lysates, distinguishing the <i>BRAF</i> wild-type and <i>BRAF</i>(V600E) tumors. …”
  19. 659
  20. 660